Objetivo
Genome sequence data present new avenues to investigate certain diseases. Such studies would be facilitated by the availability of model systems in which to test potential targets. This project is aimed at developing such systems for lysyl-tRNA synthesis, an essential pathway in protein biosynthesis. Several pathogens contain novel enzymes for lysyl-tRNA synthesis that are ideal diagnostic and therapeutic targets. Also, defects in lysyl-tRNA synthesis are responsible for some mitochondrial myopathies. Adder initial in vitro studies, genes encoding the appropriate enzymes will be used to establish Bacillus subtilis tester strains. This will provide a means to readily test predictions from in vitro studies. The final validation will be performed with the pathogens themselves and with human cell lines. The general principles of functional genomics which will be developed in this project can be readily extended to other essential pathways.
1. Bacterial class I lysyl-tRNA synthetases (KRS1). Genes encoding KRS1 were cloned from 3 pathogenic Borrelia strains which cause Lyme disease. KRS1 from B. burgdorferi was overproduced and purified for biochemical assays and antibody production;
2. Human mitochondrial lysyl-tRNA synthetase.The gene for this enzyme has been cloned by the end of the project. Human cytosolic enzyme, different only by a few amino acids at the N-terminus, has been overexpressed and used for biochemical studies;
3. Lysyl-tRNA synthetase-specific diagnostic targets and model inhibitors. The KRS1 encoding gene was validated as a diagnostic target for Lyme disease; KRS2-specific inhibitors were identified biochemically;
4. Defined in vitro system for mitochondrial Lys-tRNALys synthesis. Human mitochondrial tRNA (wild-type and variants) have been prepared by in vitro translation of the corresponding cloned genes. Since the wild-type transcript does not fold correctly, a pseudo-wild type sequence has been engineered and validated as reference molecule. Variants have been prepared on the basis of this pseudo-wild-type sequence.Optimal aminoacylation conditions have been defined;
5. Molecular basis of MERFF phenotype and of Leigh syndrome. The MERRF syndrome was shown not to be correlated to a defect in the aminoacylation properties of the mutated tRNA in vitro, nor to a structural defect of the tRNA;
6. B. subtilis strains expressing foreign lysyl- tRNA synthetase genes;
7. Comparative study of lysyl-tRNA synthetase activities in vitro and in vivo;
8. Automated diagnosis of Lyme disease. A semi-automated PCR assay was established for the identification of pathogenic Borrelia isolates. Existing antigen-based protocols were validated and adapted to the XNA platform;
9. Automated diagnosis of mitochondrial myopathies. A rapid and simple method to identify single-nucleotide polymorphisms in the human mitochondrial tRNA genes was developped. It is based on DNA/DNA hybridization on chips and has been validated with already diagnosed patient samples;
10. Interim and final progress reports. All reports were delivered as required;
11. Presentations and peer-reviewed publications. Numerous public presentations and publications in peer-reviewed journals served to disseminate project results;
12. Differential proteomic maps of healthy and disease-carrying human mitochondria. A comparative proteomic approach of wild-type and MERRF mutated mitochondria allowed to distinguish 40 proteins of mitochondrial location but of cytosolic origin, undergoing significant quantitative variations in MERRF mitochondria. These proteins may be secondary effectors of the initial mutation and their perturbations may contribute to the disease status of the cell. According to their function, quantitative increase of some of the proteins may correspond to defense mechanisms of the cell to the disease;
13.The technology for detection of specific antibodies in human serum samples advanced to a highly reproducible level by using the small synthetic peptide antigen as well as natural protein isolates. Using the same biochip surface 12 mitochondrial mutations can be detected. Automation detection has been recently achieved using a commercially available 3dimensional surface.
Ámbito científico (EuroSciVoc)
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..
- ciencias naturales ciencias biológicas genética ADN
- ciencias sociales sociología relaciones laborales automatización
- ciencias naturales ciencias biológicas genética mutación
- ciencias naturales ciencias químicas química orgánica aminas
- ciencias naturales ciencias biológicas bioquímica biomoléculas proteínas enzima
Para utilizar esta función, debe iniciar sesión o registrarse
Programa(s)
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.
Tema(s)
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.
Convocatoria de propuestas
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Datos no disponibles
Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.
Régimen de financiación
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.
Coordinador
2300 KOEPENHAGEN
Dinamarca
Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.